AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Maze Therapeutics, Inc.
Video analysis: MAZE
All videosNo video analysis for this stock yet. Request one from our team.
News: MAZE
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026. The transaction involved shares equal to 100% of the insider's directly held common stock before the filing.
Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Maze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.’s 8th Largest Position
Frazier Life Sciences Management L.P. boosted its stake in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 10.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,032,915 shares of the company's stock after acquiring an additional 465,641 shares during the period. Maze Therapeutics accounts
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m.
BlackRock Inc. Purchases Shares of 3,502,841 Maze Therapeutics, Inc. $MAZE
BlackRock Inc. purchased a new position in Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,502,841 shares of the company's stock, valued at approximately $104,525,000. BlackRock Inc. owned approximately 6.33% of Maze Therapeutics as
Bank of America Corp DE Purchases 176,703 Shares of Maze Therapeutics, Inc. $MAZE
Bank of America Corp DE increased its holdings in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 961.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 195,084 shares of the company's stock after buying an additional 176,703 shares during the period. Bank of America Corp DE
Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist
Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competition from Vertex's inaxaplin; pivotal trials are planned for 1H 2027.
ARCH Venture Management LLC Makes New $122.98 Billion Investment in Maze Therapeutics, Inc. $MAZE
ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,120,053 shares of the company's stock, valued at approximately $122,983,582,000. Maze Therapeutics accounts for about 11.2% of ARCH Venture Management
